CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
CARBON DIOXIDE, USP is an inhaled gas formulation approved as a radiographic contrast agent with X-ray contrast activity mechanism of action. It is used to enhance visualization in diagnostic imaging procedures via inhalation route. The product is a specialized diagnostic aid rather than a therapeutic drug.
Peak lifecycle stage suggests stable commercial infrastructure with mature team structure; competitive pressure at 30% indicates moderate but manageable market challenge.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Current job listings are not linked to this product, reflecting its mature, niche position in diagnostic imaging. Career opportunities exist primarily in regulatory maintenance, medical education, and product stewardship rather than growth-stage commercial expansion.